Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 4 × CAR-T Cells, A395_ID vs 4 × CAR-T Cells, DMSO_ID vs 4 × CAR-T Cells, GSK343_IDGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic MalignanciesCancer research · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE277818_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1164268 and SRA study SRP534254. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 3 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8531248 CAR-T Cells, A395_ID01 CAR-T Cells, A395_ID
- GSM8531249 CAR-T Cells, A395_ID02 CAR-T Cells, A395_ID
- GSM8531250 CAR-T Cells, DMSO_ID01 CAR-T Cells, DMSO_ID
- GSM8531251 CAR-T Cells, DMSO_ID02 CAR-T Cells, DMSO_ID
- GSM8531252 CAR-T Cells, GSK343_ID01 CAR-T Cells, GSK343_ID
- GSM8531253 CAR-T Cells, GSK343_ID02 CAR-T Cells, GSK343_ID
- GSM8531254 CAR-T Cells, A395_ID03 CAR-T Cells, A395_ID
- GSM8531255 CAR-T Cells, A395_ID04 CAR-T Cells, A395_ID
- GSM8531256 CAR-T Cells, DMSO_ID03 CAR-T Cells, DMSO_ID
- GSM8531257 CAR-T Cells, DMSO_ID04 CAR-T Cells, DMSO_ID
- GSM8531258 CAR-T Cells, GSK343_ID03 CAR-T Cells, GSK343_ID
- GSM8531259 CAR-T Cells, GSK343_ID04 CAR-T Cells, GSK343_ID
- GSE302514 Tonic Signaling Shaped by Epitope Targeting Governs CAR-T Cell Fitness and Antitumor Activity in Diffuse Midline Glioma [RNA-Seq] 10 samples shares car-t, targeting, antitumor
- GSE314992 Expression of the CXCR4 S338X variant improves anti-leukemia efficacy of anti-CD19 CAR-T cells 20 samples shares anti-cd19, car-t
- GSE254719 Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis. [RNA-Seq] 18 samples shares hematological, malignancies, targeting
- GSE254725 Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis. 23 samples shares hematological, malignancies, targeting
- GSE305732 CXCR4-modification boosts CAR-T cell efficacy by improving tumor tracking and bone marrow homing in B cell malignancies [In vitro] 20 samples shares car-t, malignancies
- GSE320375 On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy whereas preventing toxicity in glioblastoma 16 samples shares car-t, antitumor
- GSE298033 BiTE® Molecule vs. CAR-T targeting FLT3 in AML: How Positive Co-Stimulation Tips the Scale 15 samples shares car-t, targeting
- GSE320438 A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia 12 samples shares car-t, targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.